Saturday 17 October 2026
Export MLTX’s income statement to Excel — free account
MoonLake Immunotherapeutics
MLTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 3.45%, free cash flow fell 1.89% and total debt rose 35.6%, each against the same quarter a year earlier.
9.55
0.71
−6.92%
Follow MLTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.51%) | (59.99%) | (77.13%) | (67.08%) | |
| (45.14%) | (50.38%) | (56.40%) | (51.00%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(57.91%) | (60.33%) | (73.23%) | (50.21%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.93) | (3.04) | (3.14) | (3.05) | |
Free Cash Flow |
(185.90) | (196.04) | (224.15) | (225.18) | |
Capital Expenditures |
(0.21) | (0.03) | — | — | |
| Other line items | |||||
Cash ROIC |
(24.94%) | (25.38%) | (31.53%) | (21.15%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(43.56) | (33.78) | (28.15) | (26.58) | |
Operating CF/Net income |
0.88 | 0.86 | 0.87 | 0.85 | |
Depreciation/Fixed assets |
3.58 | 4.53 | 5.80 | 6.65 | |
Capex/Depreciation |
(0.09) | (0.01) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.93) | (3.04) | (3.14) | (3.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates